ARTICLE | Product Development

What’s next for neoantigens

The next act for neoantigens includes cell therapies and a broader range of targets

October 11, 2019 1:21 AM UTC

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space.

Over a dozen companies have launched programs to immunize cancer patients against mutations in their own tumors, which produce “non-self” peptide antigens akin to those from foreign pathogens. ...